Residency · Residency · Psychiatry

Social Anxiety Disorder and Specific Phobias

Social Anxiety Disorder (SAD)

Epidemiology and Course

Lifetime prevalence: ~12% (one of the most common anxiety disorders) Typical onset: early-to-mid adolescence (median age 13) Chronic course without treatment; spontaneous remission is rare. High comorbidity with MDD (up to 70% lifetime), other anxiety disorders, alcohol use disorder (self-medication) Significant functional impairment: lower educational attainment, reduced occupational achievement, impaired social relationships.

DSM-5-TR Diagnostic Criteria

Marked fear or anxiety about one or more social situations in which the individual is exposed to possible scrutiny by others. Fear of acting in a way that will be negatively evaluated (humiliated, embarrassed, rejected, offensive) Social situations almost always provoke fear or anxiety. Social situations are avoided or endured with intense fear or anxiety. Fear or anxiety is out of proportion to the actual threat. Duration >= 6 months. Causes clinically significant distress or functional impairment. Performance only specifier: fear restricted to speaking or performing in public -- important to identify because treatment approach differs.

Differentiating SAD from Avoidant Personality Disorder (AvPD)

Substantial diagnostic overlap (up to 50-90% of patients with AvPD also meet SAD criteria) AvPD: more pervasive avoidance, deeper feelings of inadequacy, more impaired relationships. SAD: may be restricted to specific performance situations. Many experts view AvPD as a severe variant of SAD rather than a categorically distinct entity. Both respond to similar treatments (CBT, SSRIs), though AvPD may require longer treatment and carry a more guarded prognosis.

Cognitive Model

Core belief: "I am socially inadequate / will be judged negatively". Anticipatory processing: catastrophic predictions before social situations. Self-focused attention during social situations (monitoring one's own behavior rather than attending to social cues) Post-event rumination: reviewing perceived failures after social interactions. Safety behaviors: avoiding eye contact, over-preparing, speaking quietly, using alcohol -- paradoxically maintain the disorder.

Treatment of Social Anxiety Disorder

Pharmacotherapy

First-line: SSRIs (sertraline, paroxetine [FDA-approved], escitalopram, fluvoxamine) or venlafaxine XR (FDA-approved) Response rates: ~50-65% (vs. ~30% placebo) Adequate trial: 8-12 weeks at therapeutic dose. Second-line: phenelzine (MAOI) -- historically the most effective pharmacotherapy, but dietary restrictions and drug interactions limit use. Adjunctive: buspirone, gabapentin/pregabalin (limited evidence) Benzodiazepines: clonazepam can be effective but risk of dependence; reserve for refractory cases. Beta-blockers (propranolol): useful ONLY for performance anxiety (blocks peripheral sympathetic symptoms: tremor, tachycardia, sweating); NOT effective for generalized SAD.

Psychotherapy

CBT: first-line psychotherapy with large effect sizes. Components: psychoeducation, cognitive restructuring (identifying and challenging negative automatic thoughts), graded exposure to feared social situations, behavioral experiments, attention retraining, dropping safety behaviors. Individual and group formats both effective; group may provide in vivo exposure opportunities. Exposure: the critical active ingredient; must be done without safety behaviors. Duration: typically 12-16 sessions. CBT and pharmacotherapy are approximately equally effective in the acute phase; CBT has more durable effects after discontinuation.

Performance Only Specifier -- Specific Management

Beta-blockers (propranolol 10-40 mg PRN, 30-60 minutes before performance) are often sufficient. Single-session or brief exposure-based interventions may be effective. Full CBT or daily pharmacotherapy may not be necessary.

Specific Phobias

Overview

Most common anxiety disorder (lifetime prevalence ~12-15%) Excessive, irrational fear of a specific object or situation. Five subtypes: animal, natural environment, blood-injection-injury (BII), situational, other. Onset: childhood for animal and BII types; later onset for situational phobias. Often present in clusters (multiple specific phobias) and commonly comorbid with other anxiety disorders.

DSM-5-TR Criteria

Marked fear or anxiety about a specific object or situation. Almost always provokes immediate anxiety. Avoided or endured with intense anxiety. Out of proportion to actual danger. Duration >= 6 months. Causes significant distress or impairment.

Blood-Injection-Injury (BII) Phobia

Unique physiology: biphasic vasovagal response (initial tachycardia followed by bradycardia and hypotension, leading to syncope) Contrasts with all other phobias where the response is purely sympathetic activation. Applied tension technique (Ost): teaches patients to tense large muscle groups to increase blood pressure and prevent fainting during exposure. Highly heritable (familial clustering stronger than other phobia subtypes)

Treatment

Exposure therapy: the gold standard and most effective treatment. In vivo exposure is preferred; graduated (systematic desensitization) or intensive (flooding) Single-session treatment (Ost): 2-3 hour session of therapist-guided exposure; cure rates of 75-90% for specific phobias. Virtual reality exposure therapy: growing evidence, particularly for height and flying phobias. Pharmacotherapy: generally NOT indicated as primary treatment for specific phobias. Occasional use of benzodiazepines for situational avoidance (e.g., flight phobia) is symptomatic but does not produce lasting change. D-cycloserine (partial NMDA agonist) studied as an augmentation agent to enhance extinction learning during exposure; mixed results.

<image> A comparison table of social anxiety disorder versus avoidant personality disorder. Two columns. For each, list: core fear, scope of avoidance (circumscribed situations vs. pervasive across all relationships), self-concept, age of onset, treatment response, DSM diagnostic category, and relationship to one another. Include a bottom note stating that many experts consider AvPD a severe variant of generalized SAD. Clinical education format. </image>

<image> A diagram of the cognitive-behavioral model of social anxiety disorder (Clark and Wells model). Show the cycle: anticipatory processing (catastrophic predictions) leads to entering the social situation with heightened self-focused attention and safety behaviors, which prevents disconfirmation of negative beliefs, followed by post-event rumination that reinforces negative self-appraisal, feeding back into anticipatory processing for the next situation. Label each component clearly. Include examples of safety behaviors (avoiding eye contact, rehearsing speech, gripping objects). Clinical education style. </image>

<image> A treatment algorithm for social anxiety disorder. Start with "Social anxiety disorder diagnosed." Branch into "Performance only" (propranolol PRN, brief exposure) vs. "Generalized." For generalized SAD: first-line is CBT or SSRI/SNRI (or both). If partial response: switch SSRI, augment, or combine CBT + pharmacotherapy. If refractory: consider phenelzine (MAOI), clonazepam. Include assessment measures (LSAS, SPIN). Flowchart format with color coding. </image>

Clinical Pearls

Social anxiety disorder is one of the most underdiagnosed and undertreated psychiatric conditions -- patients rarely present complaining of social anxiety; they present with depression, substance use, or vague functional impairment. The performance only specifier matters clinically: these patients often respond well to PRN propranolol and do not need daily medication or extended psychotherapy. Beta-blockers are NOT effective for generalized social anxiety disorder -- they only address peripheral sympathetic symptoms, not the core cognitive distortions. CBT for SAD must include exposure without safety behaviors -- cognitive restructuring alone is less effective than when combined with behavioral experiments. For specific phobias, single-session exposure therapy is remarkably effective (75-90%) and should be offered before any pharmacotherapy. Blood-injection-injury phobia is unique among phobias because it involves a vasovagal response; applied tension (not relaxation) is the appropriate physiological coping strategy.

References

• Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008;371(9618):1115-1125.
• Clark DM, Wells A. A cognitive model of social phobia. In: Heimberg RG, et al., eds. Social Phobia: Diagnosis, Assessment, and Treatment. Guilford Press; 1995.
• Mayo-Wilson E, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):368-376.
• Ost LG. One-session treatment for specific phobias. Behav Res Ther. 1989;27(1):1-7.
• Schneier FR. Social anxiety disorder. N Engl J Med. 2006;355(10):1029-1036.

Read this lecture as Markdown